Key Highlights
- MHUAF drifted modestly lower at last closing, consistent with thin OTC Liquidity rather than fresh news.
- The company reported 2025 Revenue of roughly $61.8 million, down about 36% year over year, with Net Income near $6.8 million.
- Meihua disclosed a Nasdaq delisting notice around December 2025 following a 1-for-100 reverse split that November.
- As a foreign private issuer, it reports to the SEC on Forms 20-F and 6-K rather than the domestic 10-K/10-Q cycle.
Meihua International Medical Technologies (OTC:MHUAF) is a name that now sits well off the radar of most U.S. investors, and for good reason. The China-based medical-device manufacturer was pushed off the Nasdaq in late 2025 and now changes hands in the over-the-counter market, where thin trading can produce sharp, largely mechanical price swings. A modest daily drift lower is consistent with that low-liquidity backdrop rather than any fresh company news.
Company and Latest Development
Headquartered in Yangzhou, China, Meihua International manufactures disposable medical devices spanning Class I, II and III classifications, serving hospitals and distributors primarily across Asia. As a foreign private issuer, it reports to the U.S. Securities and Exchange Commission on Forms 20-F and 6-K rather than the domestic 10-K/10-Q cycle, with a registration statement on Form F-3 filed in early 2026. The company's defining recent events have been corporate and structural: it disclosed receipt of a Nasdaq delisting notice around December 2025 and had earlier announced a 1-for-100 reverse share split in November 2025. Following the delisting, the shares migrated to the OTC market under the MHUAF symbol, having previously traded as MHUA.
What Is Driving Attention Around MHUAF?
The pullback appears to be routine price action in an Illiquid OTC security rather than a response to any verified catalyst. No fresh corporate announcement, regulatory action or financial disclosure has been identified that would explain a specific one-day move. For a stock in Meihua's situation, low float and sparse trading Volume tend to dominate short-term behavior. Investors watching MHUAF are therefore reacting mainly to its changed listing status and the mechanics of trading a former Nasdaq company that now sits in the over-the-counter tier.
Key Numbers and Company Position
Meihua remains an operating, revenue-generating business, which distinguishes it from many shell-like OTC names. For 2025 it reported revenue of roughly $61.8 million, a decline of about 36% year over year, alongside net income near $6.8 million, itself down sharply from the prior year. The market Capitalization has collapsed into the single-digit-millions range, a fraction of former levels, and the stock has fallen dramatically over the trailing year following the reverse split and delisting. Precise, current figures should be confirmed directly through Meihua's filings on SEC EDGAR, given the reporting cadence of a foreign private issuer.
What Could Come Next?
Several developments could shape the story. Meihua's future SEC filings, particularly its annual 20-F, will reveal whether revenue and margins stabilize after the 2025 decline. Any move to regain a national-exchange listing, secure new distribution agreements, or expand its device portfolio would be material. The February 2026 F-3 registration also signals potential capital-markets activity worth monitoring. For now, the trajectory hinges on operational results in China and management's response to the delisting.
Risks to Watch
The risks here are pronounced. OTC status brings reduced liquidity, wider spreads and less analyst coverage, amplifying volatility. Declining revenue and shrinking profitability raise questions about the underlying business. As a China-based issuer, Meihua carries regulatory, auditing and geopolitical exposure that has weighed on the entire cohort of U.S.-listed Chinese small caps. The reverse split and delisting also signal prior compliance struggles. Currency movements and limited public disclosure add further uncertainty for outside investors.
Distress or Overlooked Value?
Meihua International Medical Technologies is a profitable but shrinking Chinese device maker whose shares now trade over the counter after leaving the Nasdaq. The recent drift lower does not appear tied to any confirmed catalyst and likely reflects thin OTC liquidity. Investors may be watching upcoming 20-F disclosures and any listing-status developments as the factors most likely to determine whether MHUAF's depressed valuation reflects distress or overlooked value.






Please wait processing your request...